AgeX Therapeutics

AgeX Therapeutics, Inc. (commonly abbreviated as AgeX Therapeutics or simply AgeX) is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West, initially as a subsidiary of BioTime, Inc. with backing from British billionaire investor Jim Mellon and others.[1][2][3][4]

AgeX Therapeutics, Inc.
TypePublic
AMEX: AGE
IndustryBiotechnology, aging research
Founded2017
FounderMichael D. West
HeadquartersAlameda, California
Key people
Michael D. West
(CEO)
Aubrey de Grey
(VP of New Technology Discovery)
Gregory Bailey
(Chairman)
Websitewww.agexinc.com

The company's vice president of new technology discovery is Aubrey de Grey, who also serves as chief scientific officer of the SENS Research Foundation. The chairman is Gregory Bailey, who was an early backer and board member of Medivation until its acquisition by Pfizer in 2016 for $14 billion.[5][3]

In January 2020, AgeX Therapeutics announced a research collaboration with a Japanese biopharma company utilizing AgeX's UniverCyte technology platform.[6]

References
  1. "Anti-ageing drugs are coming that could keep you healthier for longer". New Scientist. April 24, 2019.
  2. "AgeX to develop powerful regenerative and anti-aging treatments". Next Big Future. December 16, 2017.
  3. "British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart". Endpoints News. July 26, 2017.
  4. "Juvenescence aims to tap longevity 'money fountain'". FT. June 11, 2018.
  5. "Pfizer to Buy Cancer Drug Maker in $14 Billion Deal". New York Times. August 22, 2016.
  6. "AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells". finance.yahoo.com. Retrieved 2020-02-24.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.